Skip to content

Assessing the Clinical Efficacy of Hyaluronic Acid Hydrogel in Papilla Augmentation: A Clinical Study.

Assessing the Clinical Efficacy of Hyaluronic Acid Hydrogel in Papilla Augmentation: A Clinical Study.

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06447311
Enrollment
24
Registered
2024-06-07
Start date
2023-04-10
Completion date
2024-06-30
Last updated
2024-06-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gingival Destruction

Brief summary

The aim of this study is to evaluate the effect of hyaluronic acid gel in papilla augmentation.

Detailed description

Assessing the clinical efficacy of Hyaluronic acid hydrogel in papilla augmentation: A clinical study. In Test group, Hyaluronic acid hydrogel will be injected using a syringe into the interdental papillary deficiency site. In Control group, saline placebo gel will be injected into the interdental papillary deficiency site using a syringe.

Interventions

Hyaluronic acid is involved in tissue repair and wound healing by stimulating cell proliferation, migration and interaction with several growth factors. Furthermore, HA has a crucial role in space-filling owing to its hygroscopic nature.

Sponsors

Dr R Viswa Chandra
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

1. Non-smoking patients aged above 18 years. 2. Have at least one site with interdental papilla recession in the anterior region (central incisors, lateral incisors and canines) of the maxillary or mandibular jaws. 3. Class I or Class II papillary recession. 4. The distance from the contact point to alveolar bone crest ≥5mm. 5. No active periodontal diseases and good oral hygiene.

Exclusion criteria

1. spacing or crowding between the teeth to be treated, 2. abnormal tooth shape, 3. systemic diseases such as diabetes mellitus, hypertension or 4. conditions that alter the outcome of periodontal therapy. 5. Pregnant and lactating women and 6. tobacco users

Design outcomes

Primary

MeasureTime frameDescription
Evaluation of papilla augmentationBaseline to 6 monthsAssessment of the empty space left by the receding interdental papilla will be measured using UNC-15 probe at baseline and post-operatively at 3 and 6 months.

Secondary

MeasureTime frameDescription
Assessment of plaquebaseline ,3months,6monthsAssessment of plaque (PI) - according to Turesky modification of Quigley and Hein Plaque Index, 1970
Assessment of gingivabaseline ,3months,6monthsGingival index (GI) - according to Loe H and Silness P, 1963

Countries

India

Contacts

Primary ContactDr.viswa chandra, MDS
viswachandra@hotmail.com8897819848

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026